Clinical Trial Update: Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation [Phase 1]

View source ↗

Summary

Phase 1 exploratory study of QR-010 in subjects with cystic fibrosis carrying the ΔF508 CFTR mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• QR-010

Snippet

Sponsor: ProQR Therapeutics | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2020-09-24